Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep554 | Hot topics (including COVID-19) | ECE2020

Patient reported changes in metabolic health during COVID-19 induced lockdown – a cross sectional digital connect survey in type 2 diabetes

Kovil Rajiv , Shah Tejas , Chawla Manoj , Karkhanis Shefali , Padhye Dakshata , Sanghvi Ami , Kale Mayura , Chawla Purvi , Prabhu Nikhil , Dhandhania Vinay , Shah Kiran

Introduction: During the COVID-19 induced lockdown it is imperative that people with T2DM be aware, disciplined, and sensitive to achieve glycemic control to mitigate the risks of COVID 19.Methods: We conducted a cross sectional survey to map the overall short-term impact of nationwide lockdown on the metabolic parameters and change in healthful behaviour patterns among patients from pooled practices of 21 diabetologists across 343 patients, with 30 ques...

ea0099ep639 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Real-world effectiveness of dapagliflozin and sitagliptin fixed-dose combination in indian patients with type 2 diabetes: a retrospective analysis of electronic medical records stratified by BMI

Kovil Rajiv , Deshmane Rajesh , Bharathi B Prakadeesh , Ahire Prachi , Kudrigikar Vinay , Dharmadhikari Shruti , Khandhedia Chintan , Markandeywar Neeraj , Mane Amey , Mehta Suyog

Introduction and Objective: Escalating prevalence of type 2 diabetes mellitus (T2D) in India presents a significant health challenge. Dapagliflozin and sitagliptin are important treatments for achieving glycaemic control in patients with T2D. Dapagliflozin promotes weight loss benefiting overweight and obese patients, while sitagliptin enhances incretin hormone activity with modest weight loss. This is a BMI-stratified analysis of electronic medical record (EMR) based real wor...